Pakistan’s Prime Minister has publicly criticized the Drug Regulatory Authority of Pakistan (DRAP) for its excessive bureaucracy and red tape. The PM expressed frustration with the slow pace of regulatory approvals, which is hindering the growth of the pharmaceutical industry. The PM stated that the government is committed to simplifying regulations and reducing bureaucratic hurdles to facilitate the growth of the industry. The PM’s criticism comes after a meeting with pharmaceutical industry stakeholders, who complained about the lengthy and complex process of obtaining regulatory approvals. The PM assured the industry stakeholders that the government will take steps to address their concerns and improve the regulatory environment. The DRAP has been criticized in the past for its slow pace of approvals, which has led to a shortage of essential medicines in the country. The PM’s criticism is seen as a positive step towards reforming the regulatory framework and promoting the growth of the pharmaceutical industry. The government has announced plans to establish a new regulatory authority to oversee the pharmaceutical industry, which will replace the DRAP. The new authority will be tasked with streamlining regulatory approvals and reducing bureaucracy. The pharmaceutical industry has welcomed the government’s plans, saying that it will help to improve the availability of essential medicines and promote the growth of the industry. However, some critics have expressed concerns that the new authority may not be able to address the underlying issues with the regulatory framework. The PM has assured that the government will work closely with industry stakeholders to ensure that the new authority is effective in promoting the growth of the industry. The government has also announced plans to increase funding for the pharmaceutical industry, which will help to promote research and development. The PM’s criticism of the DRAP has been seen as a positive step towards promoting transparency and accountability in the regulatory framework. The government has also announced plans to establish a new system for tracking and monitoring pharmaceutical products, which will help to improve the safety and efficacy of medicines. The PM has stated that the government is committed to ensuring that the pharmaceutical industry is regulated in a fair and transparent manner, and that the interests of patients and consumers are protected. The government’s plans to reform the regulatory framework have been welcomed by industry stakeholders, who say that it will help to promote the growth of the industry and improve the availability of essential medicines.